Current therapy of pulmonary hypertension

Area of Science:

• Cardiovascular Medicine
• Pulmonary Medicine
• Vascular Biology

Background:

• Pulmonary arterial hypertension (PAH) is characterized by vascular proliferation and remodeling in pulmonary arteries, leading to right ventricular failure.
• Endothelial dysfunction, involving imbalances in vasoactive mediators like prostacyclin, nitric oxide, and endothelin-1, is central to PAH pathogenesis.
• Increased pulmonary vascular resistance is a hallmark of PAH, ultimately causing significant morbidity and mortality.

Purpose of the Study:

• To review recent advances in understanding the molecular mechanisms of PAH.
• To discuss the evolution and impact of pharmacological targets and therapies developed over the past two decades.
• To evaluate the current treatment strategies and identify remaining research needs.

Main Methods:

• Review of recent scientific literature and clinical trial data on PAH.
• Analysis of molecular pathways implicated in endothelial dysfunction and vascular remodeling.
• Synthesis of evidence from placebo-controlled trials evaluating novel PAH therapeutics.

Main Results:

• Newer PAH treatments targeting specific molecular mechanisms have emerged.
• Clinical trials demonstrate improvements in patient prognosis and quality of life, with reduced mortality and morbidity.
• Despite advances, significant unmet needs remain, necessitating further long-term and comparative effectiveness research.

Conclusions:

• Targeted therapies have positively impacted PAH management.
• Continued research is crucial to optimize long-term outcomes and fully address the complexities of PAH.
• Further head-to-head trials are essential to establish definitive treatment hierarchies.